Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

We expect NVAX's FQ1'22 earnings call to be disappointing, given its minimal deliveries in the quarter. As usual, the management had overpromised and underdelivered. Again.

Novavax: Avoid This Cancer At All Costs

Novavax Inc (NASDAQ: NVAX) shares are trading lower in Monday's after-hours session after the company reported worse-than-expected financial results. Novavax reported first-quarter revenue of $704 million, which came in below the $845.2 million estimate, according to data from .

Why Novavax Shares Are Falling After Hours

Shares of Novavax Inc. dropped more than 6% in the extended session Monday after the biotech company reported its first profitable quarter, but not by as much as Wall Street expected, and its sales were also below estimates.

Earnings Results: Novavax posts first quarterly profit, but misses expectations

Novavax reported net income of $203 million in the first quarter, compared to a net loss of $222.7 million the same period last year.

Novavax posts first profitable quarter as Covid vaccine rolls out around the world

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage company Reiterating full year 2022 total revenue guidance of between $4 and $5 billion Continued label expansion including primary, booster and adolescent authorizations and new shipments of Nuvaxovid ™ into European Union, Canada, South Korea, Australia Thailand, Singapore and New Zealand Submitted request for EUA to U.S. FDA for NVX-CoV2373, with FDA Advisory Committee meeting scheduled for June 7 th Announced positive Phase 1/2 results of COVID-19-Influenza Combination vaccine candidate confirming feasibility of approach Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md.

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Novavax, Inc. (NASDAQ: NVAX) is set to print its first-quarter financial results after the market close on Thursday. The stock was trading more than 6% lower, at one point, heading into the event.

How Novavax Stock Looks Headed Into Q1 Earnings

Biogen

Moderna

UnitedHealth Group

Veru

Could these health care stocks be the remedy to investors' recent stock market pains?

Best Stocks To Buy Now? 5 Health Care Stocks In Focus

This biotech company isn't just a COVID-19 play.

Could Novavax Stock Help You Retire a Millionaire?

BioNTech SE

Palantir Technologies

Plug Power

Lordstown Motors

The first-quarter reporting season is well and truly underway. Data from Factset show that about  87% of S&P 500 companies have reported their quarterly results, with 79% reporting positive earnings per share, or EPS, surplus, and 74% ringing in revenue upside.

Palantir, Plug Power, Novavax, BioNTech, Lordstown: 5 Key Earnings To Watch Today

CrowdStrike

PayPal

These fast-paced stocks are screaming buys following a peak decline of 24% in the Nasdaq.

Nasdaq Bear Market: 3 Jaw-Dropping Growth Stocks You'll Regret Not Buying on the Dip

Novavax (NVAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Novavax (NVAX) This Earnings Season?

Is Novavax stock a buy on expectations for at least $4 billion in sales this year? Is NVAX stock a buy right now?

Novavax Guides To At Least $4 Billion In 2022 Sales — Is It A Buy Now?

Investors appear to be jumping back on the vaccine maker's bandwagon.

Why Novavax Is Crushing It This Week

GAITHERSBURG, Md. , May 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in BofA Securities 2022 Healthcare Conference.

Novavax to Participate in BofA Securities 2022 Healthcare Conference

Covid-19 vaccine developer Novavax's stock (NASDAQ: NVAX) has had a rough 2022 so far, remaining down by almost 60% year-to-date.

What's Happening With Novavax Stock?

The quarterly results and FDA approval for EUA could push NVAX stock higher in the coming weeks, so take your position now. The post Why Is Novavax Stock Rising This Week?

Why Is Novavax Stock Rising This Week?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Novavax (NVAX) Surges 19.3%: Is This an Indication of Further Gains?

A series of missteps left Novavax far behind in the vaccine race. Continued delays and roadblocks continue to hurt NVAX stock.

The Window of Opportunity Has Closed for Novavax

Novavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) to Report Q1 Results: Wall Street Expects Earnings Growth

GAITHERSBURG, Md. , May 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and operational highlights on Monday, May 9, 2022, following the close of U.S. financial markets.

Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022

Investors remain optimistic about an upcoming FDA advisory committee meeting.

Why Novavax Stock Is Soaring Today

NVAX stock is in the green after the FDA announced it would meet on June 7 to discuss the company's emergency use authorization request. The post Dear Novavax (NVAX) Stock Fans, Mark Your Calendars for June 7 appeared first on InvestorPlace.

Dear Novavax (NVAX) Stock Fans, Mark Your Calendars for June 7

Pfizer

The FDA has set up June meeting dates to review COVID-19 vaccine submissions, noting that the dates are tentative as none of the submissions are complete.   The agency reserved June 8, 21, and 22 for virtual meetings of the Vaccines and Related Biological Products Advisory.

FDA Sets Review Dates For Pfizer, Moderna COVID-19 Shot For Kids, Plus Novavax EUA

The meetings are a sign that the vaccines are moving closer to a possible authorization.

FDA panel to discuss Novavax Covid vaccine for adults, Pfizer and Moderna shots for kids in June

NVX-CoV2373 would be the first protein-based COVID-19 vaccine to be reviewed by VRBPAC in the U.S. GAITHERSBURG, Md. , April 29, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review NVX-CoV2373 COVID-19 Vaccine (recombinant, adjuvanted) for active immunization against SARS-CoV-2 at a meeting scheduled for June 7, 2022.

News for Novavax Stock (NVAX)